Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
By Ray Sison, xCell Strategic Consulting In a post-pandemic world, we need to explore a broader view of our new reality. This article shares some of the concepts currently playing out in biopharmaceutical outsourcing that will impact your CDMO selection strategy. Additional discussion touches on how new outsourcing players will fit in and the path going forward.
Alicia Levey and Kiren Khanduja of Pionyr Immunotherapeutics — a San Francisco-based biotech with a pipeline of first-in-class clinical-stage cancer immunotherapies targeting the tumor microenvironment — discuss the basis for selection of Lonza to meet Pionyr’s goals to rapidly develop a third lead candidate from the start and to scale-up manufacturing of two clinical-stage immuno-oncology treatments after tech transfer.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.